Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 1/20 | 0.55 |
| ▸ | ITGA1 | P56199 | 4/20 | 0.53 |
| ▸ | PPARG | P37231 | 5/20 | 0.52 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | AHR | P35869 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.51 |
| ▸ | PYGL | P06737 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CDK7 | P50613 | 1/20 | 0.48 |
| ▸ | CCNH | P51946 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878418 | 0.90 | ESR1 (0.55) | ESR1CYP19A1HTR6ITGA1PPARG | |
| SCHEMBL31701332 | 0.81 | ESR1 (0.61) | ESR1CYP19A1HTR6MEN1LMNA | |
| SCHEMBL3037102 | 0.80 | ESR1 (0.80) | ESR1CYP19A1HTR6CMA1AHR | |
| SCHEMBL14018648 | 0.80 | MEN1 (0.71) | ITGA1PPARGMEN1MAPTKMT2A | |
| SCHEMBL25213233 | 0.79 | AHR (0.48) | ESR1CYP19A1CMA1AHRPYGL | |
| SCHEMBL617497 | 0.79 | ESR1 (0.58) | ESR1CYP19A1HTR6MEN1LMNA | |
| SCHEMBL8278302 | 0.76 | ESR1 (0.55) | ESR1CYP19A1HTR6HDAC1HDAC8 | |
| SCHEMBL16719331 | 0.76 | ESR1 (0.78) | ESR1CYP19A1HTR6MEN1LMNA | |
| SCHEMBL4879097 | 0.74 | ITGA1 (0.51) | ITGA1PPARGMEN1LMNAMAPT | |
| SCHEMBL2029062 | 0.74 | ITGA1 (0.68) | CYP19A1ITGA1PPARGMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| EP-1732884-A1 | SULPHONAMIDE DERIVATIVES | Biotie Therapies Corp. (FI) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090298-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090297-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | NR1I2, ITGA2, ITGB2 | ESR1 195/4885CYP19A1 435/4885HTR6 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.